

CSO/NRS Restart Strategic Oversight Group

Terms of Reference

Background

On May 27th, CSO published its statement on the framework for restarting research paused due to the COVID-19 pandemic.

<https://www.cso.scot.nhs.uk/cso-statement-on-the-restart-framework/>

The CSO statement refers to the guiding principles that are contained within the NIHR Restart Framework and supported by the DA's, UK regulatory authorities, industry and 3rd sector representative bodies, and major health research charities.

<https://www.nihr.ac.uk/documents/restart-framework/24886>

CSO has established a **NRS Operational Restart Group** whose objective is to share best practice and support development of operational processes and guidance to support the resumption of non-COVID research activity across NRS. The membership of this group is comprised of senior R&D managers, NRS Network managers, and representatives from NRS CMT and CSO. The group meets weekly and convened for the first time on May 28th.

Scope and Purpose of Group Business

The purpose of the CSO/NRS COVID-19 Restart Strategic Oversight Group is to provide advice, support and guidance to CSO on all aspects of non-COVID research restart across NRS.

Members will be expected to (including, but not limited to):

- Proactively gather views and intelligence from their sectors on the progress of restart
- Provide advice on issues as requested by the NRS Operational Restart Group
- Identify and raise specific issues for the awareness of CSO and, where appropriate for the attention of the NRS Operational Restart Group
- Facilitate a collaborative working relationship amongst stakeholders involved in restart
- To take into account the framework for restarting research paused due to the COVID-19 pandemic, progression through Scottish Government's COVID-19 route map, and learning on restarting clinical research from other UK nations.
- To produce a high-level national restart strategy based on the CSO-endorsed guiding principles

Group Membership and Frequency Arrangements

The CSO/NRS COVID-19 Restart Strategic Oversight Group will be chaired by the Chief Scientist or their nominated representative.

Group membership will comprise representatives from NRS, NHS Scotland, Patients and Public, and representative bodies of key stakeholder groups

Meetings will be for 90 minutes every two weeks initially, via videoconference at the present time.

Membership

NHS R&D

Professor Julie Brittenden	NHS GG&C
Professor Maggie Cruickshank	NHS Grampian
Professor Jacob George	NHS Tayside
Professor Tim Walsh	NHS Lothian

NHS Dunfermline Group

Raymond Hamill	NHS Lanarkshire
----------------	-----------------

NRS Research Networks

Professor David Cameron	NRS Cancer
Professor Andrew Gumley	NRS Mental Health
Professor Paddy Mark	NRS Renal
Professor Jurgen Schwarze	NRS Children

NRS Biorepositories

Claire Orange	NHS GG&C
---------------	----------

NRS Safe Havens

Dr Charlie Mayor <i>Nominated deputy</i>	NHS GG&C
Katie Wilde	NHS Grampian

UKCRC-Registered CTU's

<i>Will alternate between</i>	
Professor John Cleland	Glasgow CTU
Dr Fiona Hogarth	Tayside CTU

NHS Education Scotland

Professor Adam Hill	NHS Lothian
---------------------	-------------

NHS Innovation

Dr Andrew Keen	NHS Grampian
----------------	--------------

PPI/PE

Dr Carol Porteous	University of Edinburgh
-------------------	-------------------------

